Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Capricor Therapeutics is a biotechnology business based in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Capricor Therapeutics employs 48 staff and has a trailing 12-month revenue of around $1.6 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $4.24 |
|---|---|
| 52-week range | $2.81 - $6.58 |
| 50-day moving average | $4.03 |
| 200-day moving average | $4.47 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.96 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.24 from 2023-01-27
| 1 week (2023-01-20) | -2.53% |
|---|---|
| 1 month (2022-12-28) | 21.14% |
| 3 months (2022-10-28) | -24.15% |
| 6 months (2022-07-28) | -6.19% |
| 1 year (2022-01-28) | 34.60% |
|---|---|
| 2 years (2021-01-28) | -33.54% |
| 3 years (2020-01-28) | 161.73% |
| 5 years (2018-01-26) | 102.87% |
| Revenue TTM | $1.6 million |
|---|---|
| Gross profit TTM | $-13,326,147 |
| Return on assets TTM | -36.09% |
| Return on equity TTM | -105.4% |
| Profit margin | 0% |
| Book value | $0.62 |
| Market capitalisation | $115.1 million |
TTM: trailing 12 months
We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.
Capricor Therapeutics's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.
Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $2.81 up to $6.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 4.1737. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Capricor Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
